Two Monoclonal Antibody Drugs Are Rendered Useless by Omicron


Published: January 30, 2022

The FDA has decided to restrict the use of two types of monoclonal antibody treatments. The drugs were previously made available in the U.S. because they were effective against other variants of Covid-19, but research shows that they do little to work against the Omicron variant. At this point, 99% of all positive cases in the country are due to the Omicron variant, so the drugs serve no purpose. The only monoclonal antibody treatment that has been approved for use against Omicron, sotrovimab, is available in very few places in the country.

Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.

Shop Now

Leave a Comment